ARC-6: A phase Ib/II, open-label, randomized platform study evaluating the efficacy and safety of AB928-based treatment combinations in patients with metastatic castrate resistant prostate cancer

被引：0
|
作者：
Subudhi, S. K. [1 ]
Wise, D. [2 ]
Liu, S. T. [3 ]
Chaudhry, A. [4 ]
Kim, J. [5 ]
Gardner, O. [6 ]
Gilbert, H. [6 ]
Grady, M. [6 ]
Paoloni, M. [6 ]
Krishnan, K. [6 ]
Carducci, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[2] NYU Langone Hlth, Med, New York, NY USA
[3] Univ Calif Los Angeles, Hematol Oncol, Los Angeles, CA USA
[4] Summit Canc Ctr, Med Oncol, Spokane, WA USA
[5] Yale Univ, Med Oncol, New Haven, CT USA
[6] Arcus Biosci, Clin Dept, Hayward, CA USA
[7] Johns Hopkins, Med Oncol, Baltimore, MD USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687TiP
引用
收藏
页码：S545 / S545
页数：1
相关论文
共 50 条
  • [31] MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)-based combinations in gastrointestinal (GI) cancers.
    Desai, Jayesh
    Kortmansky, Jeremy S.
    Segal, Neil Howard
    Fakih, Marwan
    Oh, Do-Youn
    Kim, Kyu-Pyo
    Rahma, Osama E.
    Ko, Andrew H.
    Chung, Hyun Cheol
    Alsina, Maria
    Yeh, Kun-Huei
    Li, Shi
    Al-Sakaff, Nedal Jaffer Abdulla
    Patel, Jilpa
    Barak, Hila
    Wang, Jun
    Zhang, Xiaosong
    Bleul, Conrad
    Cha, Edward
    Lee, Jeeyun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [32] MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types
    Chau, I.
    Haag, G. M.
    Rahma, O. E.
    Macarulla, T. M.
    McCune, S. L.
    Yardley, D. A.
    Solomon, B. J.
    Johnson, M.
    Vidal, G. A.
    Schmid, P.
    Argiles, G.
    Dimick, K.
    Mahrus, S.
    Abdullah, H.
    He, X.
    Sayyed, P.
    Barak, H.
    Bleul, C.
    Cha, E.
    Drakaki, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study
    Attard, Gerhardt
    Merseburger, Axel S.
    Arlt, Wiebke
    Sternberg, Cora N.
    Feyerabend, Susan
    Berruti, Alfredo
    Joniau, Steven
    Geczi, Lajos
    Lefresne, Florence
    Lahaye, Marjolein
    Shelby, Florence Nave
    Pissart, Genevieve
    Chua, Sue
    Jones, Robert J.
    Tombal, Bertrand
    JAMA ONCOLOGY, 2019, 5 (08) : 1159 - 1167
  • [34] A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.
    Vaishampayan, Ulka N.
    Narayan, Vivek
    Wise, David
    Lang, Joshua Michael
    Lowentritt, Benjamin H.
    Mellado, Begona
    Carles, Joan
    Saez, M. Isabel
    Abida, Wassim
    Taplin, Mary-Ellen
    Azad, Arun
    Wang, Karrie
    Barbash, Olena
    Ferron-Brady, Geraldine
    Fecteau, Doug
    Khaled, Ahmed Hussein
    Dhar, Arindam
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [35] An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
    Liu, Glenn
    Kelly, W. Kevin
    Wilding, George
    Leopold, Lance
    Brill, Kimberli
    Somer, Bradley
    CLINICAL CANCER RESEARCH, 2009, 15 (09) : 3172 - 3176
  • [36] A randomized phase II, open-label study of sipuleticel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).
    Quinn, David I.
    Petrylak, Daniel Peter
    Piaczonka, Christopher Michael
    Sandler, Andrew
    DeVries, Todd
    Sheikh, Nadeem A.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Efficacy and safety of Huachansu combined with adjuvant chemotherapy in resected colorectal cancer patients: a prospective, open-label, randomized phase II study
    Shichao Li
    Dongxiao Shen
    Qingsong Zuo
    Shengzi Wang
    Lingjia Meng
    Jiaojiao Yu
    Yang Liu
    Wusheng Li
    Chao Chen
    Peihao Yin
    Teng Chen
    Jie Wang
    Medical Oncology, 40
  • [38] Efficacy and safety of Huachansu combined with adjuvant chemotherapy in resected colorectal cancer patients: a prospective, open-label, randomized phase II study
    Li, Shichao
    Shen, Dongxiao
    Zuo, Qingsong
    Wang, Shengzi
    Meng, Lingjia
    Yu, Jiaojiao
    Liu, Yang
    Li, Wusheng
    Chen, Chao
    Yin, Peihao
    Chen, Teng
    Wang, Jie
    MEDICAL ONCOLOGY, 2023, 40 (12)
  • [39] An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer
    Salzberg, Marc
    Rochlitz, Christoph
    Morant, Rudolf
    Thalmann, George
    Pedrazzini, Augusto
    Roggero, Enrico
    Schoeneberger, Astrid
    Knuth, Alexander
    Borner, Markus
    ONKOLOGIE, 2007, 30 (07): : 355 - 360
  • [40] A randomized, open-label cecog phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab and FOLFIRI plus cetuximab as first-line therapy in metastatic colorectal cancer (MCRC)
    Ciuleanu, T.
    Scheithauer, W.
    Kurteva, G.
    Ocvirk, J.
    Koza, I
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Beslija, S.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
12345